BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li J, Huang C, Xiong T, Zhuang C, Zhuang C, Li Y, Ye J, Gui Y. A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro. Int J Biol Sci 2019;15:1276-86. [PMID: 31223286 DOI: 10.7150/ijbs.32332] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Luo M, Zhang Y, Xu Z, Lv S, Wei Q, Dang Q. Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation. Mol Med 2023;29:7. [PMID: 36647005 DOI: 10.1186/s10020-023-00608-7] [Reference Citation Analysis]
2 Meng X, Wu T, Lou Q, Niu K, Jiang L, Xiao Q, Xu T, Zhang L. Optimization of CRISPR–Cas system for clinical cancer therapy. Bioengineering & Transla Med 2022. [DOI: 10.1002/btm2.10474] [Reference Citation Analysis]
3 Du QC, Wang XY, Hu CK, Zhou L, Fu Z, Liu S, Wang J, Ma YY, Liu MY, Yu H. Integrative analysis of platelet-related genes for the prognosis of esophageal cancer. World J Clin Cases 2022; 10(33): 12077-12088 [DOI: 10.12998/wjcc.v10.i33.12077] [Reference Citation Analysis]
4 Akman B, Erkek-ozhan S. Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer. Urologic Cancers 2022. [DOI: 10.36255/exon-publications-urologic-cancers-bladder-cancer-epigenetics] [Reference Citation Analysis]
5 Gonzalez-Salinas F, Martinez-Amador C, Trevino V. Characterizing genes associated with cancer using the CRISPR/Cas9 system: A systematic review of genes and methodological approaches. Gene 2022;833:146595. [PMID: 35598687 DOI: 10.1016/j.gene.2022.146595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bouyahya A, El Hachlafi N, Aanniz T, Bourais I, Mechchate H, Benali T, Shariati MA, Burkov P, Lorenzo JM, Wilairatana P, Mubarak MS, El Omari N. Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates. Molecules 2022;27:2568. [PMID: 35458763 DOI: 10.3390/molecules27082568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Balon K, Sheriff A, Jacków J, Łaczmański Ł. Targeting Cancer with CRISPR/Cas9-Based Therapy. Int J Mol Sci 2022;23:573. [PMID: 35008996 DOI: 10.3390/ijms23010573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Mirzaei S, Paskeh MDA, Hashemi F, Zabolian A, Hashemi M, Entezari M, Tabari T, Ashrafizadeh M, Raee P, Aghamiri S, Aref AR, Leong HC, Kumar AP, Samarghandian S, Zarrabi A, Hushmandi K. Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies. Life Sci 2021;:119948. [PMID: 34520771 DOI: 10.1016/j.lfs.2021.119948] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
9 O'Garro C, Igbineweka L, Ali Z, Mezei M, Mujtaba S. The Biological Significance of Targeting Acetylation-Mediated Gene Regulation for Designing New Mechanistic Tools and Potential Therapeutics. Biomolecules 2021;11:455. [PMID: 33803759 DOI: 10.3390/biom11030455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Martinez-Escobar A, Luna-Callejas B, Ramón-Gallegos E. CRISPR-dCas9-Based Artificial Transcription Factors to Improve Efficacy of Cancer Treatment With Drug Repurposing: Proposal for Future Research. Front Oncol 2020;10:604948. [PMID: 33614489 DOI: 10.3389/fonc.2020.604948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Semin Cancer Biol 2020:S1044-579X(20)30176-0. [PMID: 32814115 DOI: 10.1016/j.semcancer.2020.07.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
12 Rahman MM, Tollefsbol TO. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects. Methods 2021;187:77-91. [PMID: 32315755 DOI: 10.1016/j.ymeth.2020.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
13 Liao C, Long Z, Zhang X, Cheng J, Qi F, Wu S, Huang T. LncARSR sponges miR-129-5p to promote proliferation and metastasis of bladder cancer cells through increasing SOX4 expression. Int J Biol Sci 2020;16:1-11. [PMID: 31892841 DOI: 10.7150/ijbs.39461] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]